Expressions of Galectin-3 and Cytokeratin-19 in Different Tissues of Hashimoto Thyroiditis Complicated with Papillary Thyroid Microcarcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

XU Qiyin ,  CHENG Ruochuan

Department of Gastrointestinal and Thyroid Surgery， The First Affiliated Hospital of Kunming Medical University， Kunming 650031， Yunnan Province， China;

Corresponding author：

CHENG Ruochuan, Email: cruochuan@yahoo.com.cn

Keywords：

Galectin-3; Cytokeratin-19; Hashimoto thyroiditis; Papillary thyroid microcarcinoma

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To explore the expressions of galectin-3 （Gal-3） and cytokeratin-19 （CK-19） in different tissues of Hashimoto thyroiditis （HT） complicated with papillary thyroid microcarcinoma （PTMC）.
Methods 　The tumor tissue， 0.5 cm near tumor tissue， and opposite lateral lobe thyroid tissue in 25 HT with benign nodus patients， 25 PTMC patients， and 25 HT with PTMC patients were collected. The expressions of Gal-3 and CK-19 in these tissues were detected by immunohistochemical methods.
Results 　①The positive rates of Gal-3 and CK-19 expressions in the tumor tissue
of HT with PTMC patients and PTMC patients were significantly higher than those of HT with benign nodus patients （P＜0.05）.②The positive rates of Gal-3 and CK-19 expressions in the opposite lateral lobe thyroid tissue of HT with PTMC patients and HT with benign nodus patients were significantly higher than those of PTMC patients （P＜0.05）．③The positive rates of Gal-3 and CK-19 expressions in the 0.5 cm near tumor tissue of HT with PTMC patients and HT with benign nodus patients were significantly higher than those of PTMC patients （P＜0.05）. ④The middle and b positive rates of Gal-3 and CK-19 expressions in the 0.5 cm near tumor tissue of HT with PTMC patients were significantly higher than those of HT with benign nodus patients and the PTMC patients （P＜0.05）．
Conclusions 　①Gal-3 and CK-19 protein are helpful to differentiate the benign thyroid tumor and malignant one. ② The expressions of Gal-3 and CK-19 protein in patients with HT are clear higher than those in patients without HT that means the prognosis evaluation in HT canceration. ③ Gal-3 combined with CK-19 protein are help for early diagnosis， the pathogenesis and prognosis evaluation in thyroid cancer. The b positive means canceration. ④ In HT with PTMC， it needs an operation therapy and a larger one， which is appropriate for lateral and opposite lobe partial resection or total resection.

Citation： XU Qiyin,CHENG Ruochuan. Expressions of Galectin-3 and Cytokeratin-19 in Different Tissues of Hashimoto Thyroiditis Complicated with Papillary Thyroid Microcarcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2013, 20(2): 161-164. doi: Copy

1.	Beesley MF， McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules[J]. Histopathology， 2002， 41(3)：236-243.
2.	Lindsay S， Dailey ME， Friedlander J， et al. Chronic thyroiditis：a clinical and pathologic study of 354 patients[J]. J Clin Endocrinol Metab， 1952， 12(12)：1578-1600.
3.	Arif S， Blanes A， Diaz-Cano SJ. Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma[J]. Histopathology， 2002， 41(4)：357-362.
4.	王兰，潘丹. 桥本甲状腺炎伴甲状腺癌临床病理分析[J]. 临床与实验病理学杂志， 2003， 19(3)：286-289.
5.	Khalil A， Kaufmann RC， Wortsman J， et al. Inhibin in normal and abnormal pregnancy：maternal serum concentration andpartial characterization[J]. Am J Obstet Gynecol， 1995， 172((3)：1019-1025.
6.	Honjo Y， Inohara H， Akahani S， et al. Expression of cytoplasmicgalectin-3 as a prognostic marker in tongue carcinoma[J]. Clin Cancer Res， 2000， 6(12)：4635-4640.
7.	Xu XC， el-Naggar AK， Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications[J]. Am J Pathol， 1995， 147(3)：815-822.
8.	Bartolazzi A， Gasbarri A， Papotti M， et al. Application of animmunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions[J]. Lancet， 2001， 357(9269)：1644-1650.
9.	Perillo NL， Marcus ME， Baum LG. Galectins：versatile modulators of cell adhesion， cell proliferation， and cell death[J]. J Mol Med， 1998， 76(6)：402-412.
10.	Nangia-Makker P， Honjo Y， Sarvis R， et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis[J]. Am J Pathol， 2000， 156(3)：899-909.
11.	彭年春，郭晓蕙，袁振芳，等. CD26/DPPⅣ、galectin-3在甲状腺乳头状癌的表达及意义[J]. 基础医学与临床， 2009， 29(10)：1079-1082.
12.	Rosaí J， Zampi G， Carcangiu ML. Papillary carcinoma of the thyroid. A discussion of its several morphologic expressions， with particular emphasis on the follicular variant[J]. Am J Surg Pathol， 1983， 7(8)：809-817.
13.	Sahoo S， Hoda SA， Rosai J， et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma：a note of caution[J]. Am J Clin Pathol， 2001， 116(5)：696-702.
14.	Miettinen M， Kovatich AJ， Kärkkäinen P. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications[J]. Virchows Arch， 1997， 431(6)：407-413.
15.	贾万钧，郭艳. CK19、gal-3、HBME-1和Ret蛋白在甲状腺乳头状癌中的表达[J]. 浙江临床医学， 2007， 9(11)：1143-1144.
16.	王仪，魏霖，陈昕. Galectin-3、CK19和MC在甲状腺良、恶性肿瘤中的表达及意义[J]. 海峡药学， 2007， 19(12)：108-110.
17.	Kazantseva IA， Fedosenko AK， Gurevich LE. Immunohistochemical study in differential diagnosis of benign and malignant lesions of the thyroid gland[J]. Arkh Patol， 2001， 63(4)：18-21.
18.	王家耀. 桥本甲状腺炎与甲状腺癌的关系[J]. 诊断病理学杂志， 1997， 4(2)：106-107.
19.	戴军，陈方荟，包建东，等. 桥本甲状腺炎癌变与甲状腺乳头状癌相关性分析[J]. 诊断病理学杂志， 2005， 12(6)：458-459， 501.
20.	Di Pasquale M， Rothstein JL， Palazzo JP. Pathologic features of Hashimoto’s-associated papillary thyroid carcinomas[J]. Hum Pathol， 2001， 32(1)：24-30.

1. Beesley MF， McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules[J]. Histopathology， 2002， 41(3)：236-243.
2. Lindsay S， Dailey ME， Friedlander J， et al. Chronic thyroiditis：a clinical and pathologic study of 354 patients[J]. J Clin Endocrinol Metab， 1952， 12(12)：1578-1600.
3. Arif S， Blanes A， Diaz-Cano SJ. Hashimoto’s thyroiditis shares features with early papillary thyroid carcinoma[J]. Histopathology， 2002， 41(4)：357-362.
4. 王兰，潘丹. 桥本甲状腺炎伴甲状腺癌临床病理分析[J]. 临床与实验病理学杂志， 2003， 19(3)：286-289.
5. Khalil A， Kaufmann RC， Wortsman J， et al. Inhibin in normal and abnormal pregnancy：maternal serum concentration andpartial characterization[J]. Am J Obstet Gynecol， 1995， 172((3)：1019-1025.
6. Honjo Y， Inohara H， Akahani S， et al. Expression of cytoplasmicgalectin-3 as a prognostic marker in tongue carcinoma[J]. Clin Cancer Res， 2000， 6(12)：4635-4640.
7. Xu XC， el-Naggar AK， Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications[J]. Am J Pathol， 1995， 147(3)：815-822.
8. Bartolazzi A， Gasbarri A， Papotti M， et al. Application of animmunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions[J]. Lancet， 2001， 357(9269)：1644-1650.
9. Perillo NL， Marcus ME， Baum LG. Galectins：versatile modulators of cell adhesion， cell proliferation， and cell death[J]. J Mol Med， 1998， 76(6)：402-412.
10. Nangia-Makker P， Honjo Y， Sarvis R， et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis[J]. Am J Pathol， 2000， 156(3)：899-909.
11. 彭年春，郭晓蕙，袁振芳，等. CD26/DPPⅣ、galectin-3在甲状腺乳头状癌的表达及意义[J]. 基础医学与临床， 2009， 29(10)：1079-1082.
12. Rosaí J， Zampi G， Carcangiu ML. Papillary carcinoma of the thyroid. A discussion of its several morphologic expressions， with particular emphasis on the follicular variant[J]. Am J Surg Pathol， 1983， 7(8)：809-817.
13. Sahoo S， Hoda SA， Rosai J， et al. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma：a note of caution[J]. Am J Clin Pathol， 2001， 116(5)：696-702.
14. Miettinen M， Kovatich AJ， Kärkkäinen P. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications[J]. Virchows Arch， 1997， 431(6)：407-413.
15. 贾万钧，郭艳. CK19、gal-3、HBME-1和Ret蛋白在甲状腺乳头状癌中的表达[J]. 浙江临床医学， 2007， 9(11)：1143-1144.
16. 王仪，魏霖，陈昕. Galectin-3、CK19和MC在甲状腺良、恶性肿瘤中的表达及意义[J]. 海峡药学， 2007， 19(12)：108-110.
17. Kazantseva IA， Fedosenko AK， Gurevich LE. Immunohistochemical study in differential diagnosis of benign and malignant lesions of the thyroid gland[J]. Arkh Patol， 2001， 63(4)：18-21.
18. 王家耀. 桥本甲状腺炎与甲状腺癌的关系[J]. 诊断病理学杂志， 1997， 4(2)：106-107.
19. 戴军，陈方荟，包建东，等. 桥本甲状腺炎癌变与甲状腺乳头状癌相关性分析[J]. 诊断病理学杂志， 2005， 12(6)：458-459， 501.
20. Di Pasquale M， Rothstein JL， Palazzo JP. Pathologic features of Hashimoto’s-associated papillary thyroid carcinomas[J]. Hum Pathol， 2001， 32(1)：24-30.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expressions of Galectin-3 and Cytokeratin-19 in Different Tissues of Hashimoto Thyroiditis Complicated with Papillary Thyroid Microcarcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content